Antihyperglycemic Effect of Ginkgo biloba Extract in Streptozotocin-Induced Diabetes in Rats

Table 3

Effect of GBE treatment on hepatic and pancreatic oxidative stress markers of rats in experimental groups.

	N group	D group	N + G group	D + LG group	D + MG group	D + HG group	D + GLI group
Liver
GSH (μg/mg protein)	512.36 ± 91.25	365.50 ± 84.77^a	529.36 ± 101.23^b	400.28 ± 79.46	451.33 ± 89.44^c	486.36 ± 98.31^b	482.09 ± 106.30^c
CAT (U/mg protein)	362.63 ± 18.52	302.05 ± 22.82^a	374.47 ± 26.36^b	313.25 ± 24.47	322.52 ± 17.52^c	349.96 ± 25.01^b	344.80 ± 20.91^b
SOD (U/mg protein)	542.35 ± 24.21	235.27 ± 34.22^a	602.0 ± 40.50^b	322.21 ± 32.65^b	414.11 ± 35.33^b	505.20 ± 41.52^b	523.36 ± 36.66^b
GSH-Px (U/mg protein)	3023 ± 217	2236 ± 259^a	3111 ± 285^b	2567 ± 198^b	2758 ± 252^b	2904 ± 220^b	2808 ± 244^b
MDA (nmol/mg protein)	9.03 ± 1.25	16.91 ± 1.81^a	8.85 ± 1.33^b	14.28 ± 1.57^b	10.05 ± 1.01^b	9.66 ± 1.41^b	10.36 ± 1.55^b
Pancreas
GSH (μg/mg protein)	444.08 ± 71.44	294.14 ± 69.27^a	408.50 ± 66.85^b	312.58 ± 75.55	360.00 ± 57.19^c	405.81 ± 63.36^b	406.16 ± 56.39^b
CAT (U/mg protein)	298.02 ± 21.30	174.22 ± 14.52^a	287.34 ± 22.71^b	196.35 ± 18.90^b	209.42 ± 23.00^b	212.56 ± 20.66^b	274.30 ± 21.94^b
SOD (U/mg protein)	415.00 ± 33.20	197.38 ± 36.55^a	385.52 ± 32.11^b	222.44 ± 36.40	356.78 ± 37.80^b	379.91 ± 38.92^b	364.82 ± 40.24^b
GSH-Px (U/mg protein)	658 ± 89	462 ± 92^a	711 ± 101^b	555 ± 74^c	596 ± 94^b	623 ± 78^b	539 ± 79^b
MDA (nmol/mg protein)	8.77 ± 1.03	14.91 ± 1.44^a	8.05 ± 1.11^b	12.50 ± 1.48^b	10.87 ± 1.61^b	9.22 ± 1.31^b	8.99 ± 1.40^b

Values are means ± SD for 10 rats in each group. N group: normal control; D group: diabetes group; N + G group: normal control plus GBE; D + LG group: diabetes plus low GBE treatment; D + MG group: diabetes plus middle GBE treatment; D + HG group: diabetes plus high GBE treatment; D + GLI group: diabetes plus glibenclamide treatment.
^aIndicates statistical significance of 𝑃<0.01 compared to N group; ^b𝑃<0.01 compared to D group.
^c𝑃<0.05 compared to D group.